Bansal S, Prabhash K, Parikh P (2013) Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol 34(3):154–158

Article  PubMed  PubMed Central  Google Scholar 

Ganesan P, Kumar L (2017) Chronic myeloid leukemia in India. J Glob Oncol 3(1):64–71

Article  PubMed  Google Scholar 

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8(5):935–942

CAS  PubMed  Google Scholar 

Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O’Brien S, So C, Massimini G, Guilhot F (2006) Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108(5):1478–1484

Article  CAS  PubMed  Google Scholar 

Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, J Am Soc Hematol 119(9):1981–1987

CAS  Google Scholar 

Hochhaus A, Kreil S, Corbin AS, La Rosee P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11):2190–2196

Article  CAS  PubMed  Google Scholar 

Jabbour E, Kantarjian H, Jones D et al (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767–1773

Article  CAS  PubMed  Google Scholar 

Alves R, Gonçalves AC, Rutella S, Almeida AM, De Las RJ, Trougakos IP, Sarmento Ribeiro AB (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance. Cancers 13(19):4820

Article  CAS  PubMed  PubMed Central  Google Scholar 

Von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359(9305):487–491

Article  Google Scholar 

Branford S, Rudzki Z, Walsh S et al (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9):3472–3475

Article  CAS  PubMed  Google Scholar 

Shah NP, Nicoll JM, Nagar B et al (2002) Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117–125

Article  CAS  PubMed  Google Scholar 

Nicolini FE, Ibrahim AR, Soverini S et al (2013) The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 98:1510–1516

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242–2249

Article  CAS  PubMed  Google Scholar 

Redaelli S, Piazza R, Rostagno R et al (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib resistant BCR/ABL mutants. J Clin Oncol 27:469–471

Article  CAS  PubMed  Google Scholar 

O’Brien S, Abboud CN, Akhtari M et al Clinical Practice Guidelines in Oncology.Chronic myelogenous leukemia, Version 2.2014, National Comprehensive Cancer Network (NCCN). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105/. Accessed 01/03/2024

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–84

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mishra K, Yanamandra U, Shukla A, Pramanik SK, Kapoor R, Das S (2019) Risk stratification of CML-CP in a real-world scenario, comparison of SHE with rate of fall of BCR/ABL. Ann Oncol 30:ix95

Article  Google Scholar 

Zhang XS, Gale RP, Huang XJ, Jiang Q (2022) Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia 36(2):482–491

Article  PubMed  Google Scholar 

Sharma P, Mohanty S, Kochupillai V et al (2010) Mutations in ABL kinase domain are associated with inferior progression free survival. Leuk Lymphoma 51:1072–1078

Article  CAS  PubMed  Google Scholar 

Babu G (2013) Report of patients with chronic myeloid leukemia Kidwai memorial institute of oncology Bangalore over 15 years. Indian J Med Paediatr Oncol 34(3):196–198

Article  PubMed  PubMed Central  Google Scholar 

Sinha SK, Sinha S, Mandal PK et al (2013) A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers. Indian J Pathol Microbiol 56:216–220

Article  PubMed  Google Scholar 

Patkar N, Ghodke K, Joshi S, Chaudhary S, Mascerhenas R, Dusseja S, Mahadik S, Gaware S, Tembhare P, Gujral S, Kabre S (2016) Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. Leuk Lymphoma 57(11):2653–2660

Article  CAS  PubMed  Google Scholar 

Tripathi AK, Verma SP, Kumar N (2017) Mutation analysis in chronic myeloid leukemia patient in chronic phase on imatinib having delayed achievement of milestones or loss of response. Indian J Hematol Blood Transfus 33:316–320

Article  CAS  PubMed  Google Scholar 

Chaitanya PK, Kumar KA, Stalin B, Sadashivudu G, Srinivas ML (2017) The Role of Mutation Testing in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Failure and Their Outcomes after Treatment Modification: Single-institutional Experience Over 13 Years. Indian J Med Paediatr Oncol 38(03):328–333

Article  PubMed  PubMed Central  Google Scholar 

Palukuri NR, Stalin B, Chennamaneni R, Prasad SK, Konatam ML, Gundeti S (2019) Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation. Ann Oncol 30:v444

Google Scholar 

Bommannan KB, Naseem S, Binota J, Varma N, Malhotra P, Varma S (2022) Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience. J Postgrad Med 68(2):93

Article  CAS  PubMed  Google Scholar 

Kagita S, Uppalapati S, Jiwatani S et al (2014) Incidence of BCR-ABL kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol 35:7187–7193

Article  CAS  PubMed  Google Scholar 

Benjamin C, Murugan S, Hoosen S, Rapiti N (2023) Chronic myeloid leukemia kinase domain mutations: A retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa. Health Sci Rep 6(7):e1376

Article  PubMed  PubMed Central  Google Scholar 

Erbilgin Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, Elverdi T, Firtina S, Tasar O, Mercan S, Sisko S, Khodzhaev K, Ongoren S (2019) Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leuk Lymphoma 60(1):200–207

Article  CAS  PubMed  Google Scholar 

Etienne G, Dulucq S, Huguet F, Schmitt A, Lascaux A, Hayette S, Fort MP, Sujobert P, Bijou F, Morisset S, Tavitian S (2019) Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Med 8(11):5173

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of ABL kinase domain mutations in imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA working party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374–7379

Article  CAS  PubMed  Google Scholar 

Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T (2006) Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi (ϕ)-LMC GROUP). Leukemia 20(6):1061–1066

Article  CAS  PubMed  Google Scholar 

Markose P, Chendamarai E, Balasubramanian P, Velayudhan SR, Srivastava VM, Mathews V, George B, Viswabandya A, Srivastava A, Chandy M (2009) Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leuk Lymphoma 50(12):2092–2095

Article  CAS  PubMed  Google Scholar 

Rajappa S, Mallavarapu KM, Gundeti S, Roshnipaul T, Jacob RT, Digumarti R (2010) Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. Leuk Lymphoma 51(1):79–84

Article  CAS  PubMed  Google Scholar 

Srivastava S, Dutt S (2013) Imatinib mesylate resistance and mutations: An Indian experience. Indian J Med Paediatr Oncol 34(03):213–220

Article  PubMed  PubMed Central  Google Scholar 

Mukhopadhyay S, Dasgupta S, Mitra P, Bose CK, Gharami FH, Mukhopadhyay A (2015) 310P Correlation of different mutations with drug resistance in chronic myeloid leukemia in Indian perspective. Ann Oncol 26:ix85